ENTRADA THERAPEUTICS INC (TRDA) Fundamental Analysis & Valuation

NASDAQ:TRDA • US29384C1080

11.97 USD
+0.12 (+1.01%)
Last: Mar 4, 2026, 10:23 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This TRDA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Overall TRDA gets a fundamental rating of 3 out of 10. We evaluated TRDA against 520 industry peers in the Biotechnology industry. While TRDA has a great health rating, there are worries on its profitability. TRDA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. TRDA Profitability Analysis

1.1 Basic Checks

  • In the past year TRDA has reported negative net income.
  • TRDA had a negative operating cash flow in the past year.
  • In the past 5 years TRDA reported 4 times negative net income.
  • In the past 5 years TRDA reported 4 times negative operating cash flow.
TRDA Yearly Net Income VS EBIT VS OCF VS FCFTRDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

1.2 Ratios

  • TRDA has a Return On Assets of -25.06%. This is in the better half of the industry: TRDA outperforms 70.38% of its industry peers.
  • TRDA has a Return On Equity of -30.36%. This is in the better half of the industry: TRDA outperforms 74.42% of its industry peers.
Industry RankSector Rank
ROA -25.06%
ROE -30.36%
ROIC N/A
ROA(3y)-8.83%
ROA(5y)-20.84%
ROE(3y)-10.65%
ROE(5y)-23.01%
ROIC(3y)N/A
ROIC(5y)N/A
TRDA Yearly ROA, ROE, ROICTRDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for TRDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRDA Yearly Profit, Operating, Gross MarginsTRDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. TRDA Health Analysis

2.1 Basic Checks

  • TRDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TRDA has more shares outstanding than it did 1 year ago.
  • TRDA has more shares outstanding than it did 5 years ago.
  • TRDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TRDA Yearly Shares OutstandingTRDA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
TRDA Yearly Total Debt VS Total AssetsTRDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • TRDA has an Altman-Z score of 3.06. This indicates that TRDA is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.06, TRDA is doing good in the industry, outperforming 67.31% of the companies in the same industry.
  • There is no outstanding debt for TRDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.06
ROIC/WACCN/A
WACC8.69%
TRDA Yearly LT Debt VS Equity VS FCFTRDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 14.08 indicates that TRDA has no problem at all paying its short term obligations.
  • TRDA's Current ratio of 14.08 is amongst the best of the industry. TRDA outperforms 90.00% of its industry peers.
  • TRDA has a Quick Ratio of 14.08. This indicates that TRDA is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 14.08, TRDA belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.08
Quick Ratio 14.08
TRDA Yearly Current Assets VS Current LiabilitesTRDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. TRDA Growth Analysis

3.1 Past

  • TRDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -256.60%.
  • Looking at the last year, TRDA shows a very negative growth in Revenue. The Revenue has decreased by -71.42% in the last year.
EPS 1Y (TTM)-256.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-202.86%
Revenue 1Y (TTM)-71.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-91.75%

3.2 Future

  • The Earnings Per Share is expected to decrease by -24.43% on average over the next years. This is quite bad
  • The Revenue is expected to decrease by -18.76% on average over the next years. This is quite bad
EPS Next Y-302.72%
EPS Next 2Y-105.92%
EPS Next 3Y-62.65%
EPS Next 5Y-24.43%
Revenue Next Year-83.28%
Revenue Next 2Y-55.02%
Revenue Next 3Y-33.26%
Revenue Next 5Y-18.76%

3.3 Evolution

TRDA Yearly Revenue VS EstimatesTRDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2029 2030 2031 2032 2033 200M 400M 600M
TRDA Yearly EPS VS EstimatesTRDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. TRDA Valuation Analysis

4.1 Price/Earnings Ratio

  • TRDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRDA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRDA Price Earnings VS Forward Price EarningsTRDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRDA Per share dataTRDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

  • TRDA's earnings are expected to decrease with -62.65% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-105.92%
EPS Next 3Y-62.65%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TRDA Dividend Analysis

5.1 Amount

  • No dividends for TRDA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TRDA Fundamentals: All Metrics, Ratios and Statistics

ENTRADA THERAPEUTICS INC

NASDAQ:TRDA (3/4/2026, 10:23:26 AM)

11.97

+0.12 (+1.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-18
Inst Owners76.47%
Inst Owner Change1.15%
Ins Owners0.73%
Ins Owner Change-5.55%
Market Cap457.49M
Revenue(TTM)61.52M
Net Income(TTM)-103.46M
Analysts85
Price Target18.87 (57.64%)
Short Float %2.77%
Short Ratio4.21
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.43%
Min EPS beat(2)-20.31%
Max EPS beat(2)-10.55%
EPS beat(4)2
Avg EPS beat(4)30.34%
Min EPS beat(4)-20.31%
Max EPS beat(4)104.39%
EPS beat(8)5
Avg EPS beat(8)158.15%
EPS beat(12)7
Avg EPS beat(12)114.61%
EPS beat(16)8
Avg EPS beat(16)87.54%
Revenue beat(2)0
Avg Revenue beat(2)-84.32%
Min Revenue beat(2)-88.45%
Max Revenue beat(2)-80.19%
Revenue beat(4)2
Avg Revenue beat(4)27.24%
Min Revenue beat(4)-88.45%
Max Revenue beat(4)179.44%
Revenue beat(8)6
Avg Revenue beat(8)78.29%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.12%
PT rev (3m)12.12%
EPS NQ rev (1m)-17.59%
EPS NQ rev (3m)-16.16%
EPS NY rev (1m)-5.3%
EPS NY rev (3m)-7.54%
Revenue NQ rev (1m)-21.4%
Revenue NQ rev (3m)-21.4%
Revenue NY rev (1m)-4.4%
Revenue NY rev (3m)-20.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.44
P/FCF N/A
P/OCF N/A
P/B 1.34
P/tB 1.34
EV/EBITDA N/A
EPS(TTM)-2.49
EYN/A
EPS(NY)-4.28
Fwd EYN/A
FCF(TTM)-3.41
FCFYN/A
OCF(TTM)-3.36
OCFYN/A
SpS1.61
BVpS8.91
TBVpS8.91
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.06%
ROE -30.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-8.83%
ROA(5y)-20.84%
ROE(3y)-10.65%
ROE(5y)-23.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.95%
Cap/Sales 3.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.08
Quick Ratio 14.08
Altman-Z 3.06
F-Score2
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)144.47%
Cap/Depr(5y)309.68%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-256.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-202.86%
EPS Next Y-302.72%
EPS Next 2Y-105.92%
EPS Next 3Y-62.65%
EPS Next 5Y-24.43%
Revenue 1Y (TTM)-71.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-91.75%
Revenue Next Year-83.28%
Revenue Next 2Y-55.02%
Revenue Next 3Y-33.26%
Revenue Next 5Y-18.76%
EBIT growth 1Y-313.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-791.76%
EBIT Next 3Y-147.29%
EBIT Next 5YN/A
FCF growth 1Y-217.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-210.18%
OCF growth 3YN/A
OCF growth 5YN/A

ENTRADA THERAPEUTICS INC / TRDA FAQ

Can you provide the ChartMill fundamental rating for ENTRADA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to TRDA.


What is the valuation status for TRDA stock?

ChartMill assigns a valuation rating of 0 / 10 to ENTRADA THERAPEUTICS INC (TRDA). This can be considered as Overvalued.


How profitable is ENTRADA THERAPEUTICS INC (TRDA) stock?

ENTRADA THERAPEUTICS INC (TRDA) has a profitability rating of 1 / 10.


What is the financial health of ENTRADA THERAPEUTICS INC (TRDA) stock?

The financial health rating of ENTRADA THERAPEUTICS INC (TRDA) is 8 / 10.